Provided by Tiger Trade Technology Pte. Ltd.

JUNSHI BIO

17.460
-0.430-2.40%
Volume:2.04M
Turnover:36.31M
Market Cap:17.93B
PE:-20.07
High:18.500
Open:18.400
Low:17.320
Close:17.890
52wk High:31.800
52wk Low:15.250
Shares:1.03B
HK Float Shares:260.00M
Volume Ratio:2.18
T/O Rate:0.79%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.870
ROE:-9.32%
ROA:-2.89%
PB:2.58
PE(LYR):-20.07
PS:5.06

Loading ...

Junshi Bio Reorganises R&D Vehicle Junyan Hongshi; Controlled VC Arm Injects RMB0.10 Billion for 9.09% Stake

Bulletin Express
·
Jun 05

Junshi Bio to Close H-Share Register 23–26 June 2026 Ahead of 2025 AGM

Bulletin Express
·
Jun 05

Shanghai Junshi Biosciences - Approved Proposal on Change in Shareholding Structure of Implementing Entity of Some Sub-Projects

THOMSON REUTERS
·
Jun 05

Shanghai Junshi Biosciences - Junyan Hongshi Intends to Increase Its Registered Capital by RMB100 Mln

THOMSON REUTERS
·
Jun 05

Junshi Biosciences Updates Board Composition and Committee Structure

Bulletin Express
·
Jun 05

JUNSHI BIO Announces 2025 Annual General Meeting Scheduled for June 26, 2026

Deep News
·
Jun 05

Junshi Bio Maintains Stable Share Base in May; 13.21 Million H-Share Options Outstanding

Bulletin Express
·
Jun 03

AH Share Premium and Deviation Rankings as of June 1st

Stock News
·
Jun 01

Junshi Biosciences Drug Meets Main Goal of Lung Cancer Study

MT Newswires Live
·
May 27

BRIEF-Shanghai Junshi Biosciences Says Toripalimab Met Primary Endpoint

Reuters
·
May 26

JUNSHI BIO’s Toripalimab Hits Primary Endpoints in Phase III NEOTORCH Trial for Stage II-III NSCLC

Bulletin Express
·
May 26

JUNSHI BIO (01877): Phase III Study of Toripalimab with Chemotherapy in Perioperative Treatment for Resectable Stage II-III Non-Small Cell Lung Cancer Meets Primary Endpoints in Final Analysis

Stock News
·
May 26

Shanghai Junshi Biosciences - Toripalimab as Perioperative Treatment for Resectable Stage Ii-Iii Nsclc- Patients Met Primary Endpoint

THOMSON REUTERS
·
May 26

Junshi Biosciences Gets Nod for New Indication for Toripalimab; Shares Down 4%

MT Newswires Live
·
May 22

Shanghai Junshi Biosciences - Approval of Supplemental New Drug Application of Toripalimab

THOMSON REUTERS
·
May 21

Stock Track | JUNSHI BIO Soars 5.23% Intraday on Strong Q1 Earnings Showing Revenue Up 45% and Net Loss Narrowing Over 90%

Stock Track
·
May 11

JUNSHI BIO Nears Profitability, Yet Secondary Market Remains Skeptical: Can It Achieve Critical Valuation Rebound?

Stock News
·
Apr 29

Stock Track | Junshi Bio Soars 5.06% Intraday on ESOP Approval and Q1 Financial Results

Stock Track
·
Apr 28

JUNSHI BIO Shares Climb Over 3% Following Earnings Report

Stock News
·
Apr 28

BRIEF-Shanghai Junshi Biosciences Posts Quarterly Net Loss Attributable RMB20.6 Million

Reuters
·
Apr 27